The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussion presentation by Dr. Niven Mehra discussing three abstracts including “Efficacy and safety of darolutamide plus ADT in patients with mHSPC from the phase 3 ARANOTE trial” by Dr. Fred Saad, “Prostate cancer efficacy results from a randomized phase 3 evaluation of transdermal estradiol versus LHRH ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Mamta Parikh discussed Emerging Therapeutics: Combination Therapy in the Neoadjuvant Setting for Bladder Cancer.

ASCO GU 2024 results of a European real-world analysis of the safety and efficacy of enfortumab vedotin (EV) in patients with metastatic/locally advanced urothelial cancer, monomethyl auristatin E (MMAE), combination EV + pembrolizumab.

EAU 2024 Bladder Cancer. EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response

ASCO GU 2024 Bladder Cancer. ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery; ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

About UroToday-GU Oncology Today ® UroToday - GU Oncology Today brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.This site presents content on critical areas of research and clinical practice, providing researchers and clinicians the opportunity to evaluate …

Oct 17, 2024 · ESMO 2024, metastatic castration resistant prostate cancer (mCRPC), SPLASH trial,177Lu-PSMA-617, PSMAfore trial, 177Lu-PNT2002, enzalutamide, abiraterone, VISION trial, androgen receptor pathway inhibitor (ARPI).

2 days ago · January 28, 2025 . The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEGFR-TKI) now set as the standard front-line treatment …

6 days ago · In prostate cancer patients, high radiation doses to the urethra have been associated with an increased risk of severe genitourinary toxicity following dose-escalated radiotherapy. Urethra-sparing techniques have emerged as a promising approach to reduce urinary toxicity.